Geva Ravit - Service for Gastrointestinal Malignancies, Tel-Aviv Sourasky Medical Center

基本信息

浏览量：106

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 230 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

990O Final Results from Phase I, First-in-human, Dose Escalation Study of a First-in-class Anti-Ilt2 Antibody, SAR444881, Alone and with Pembrolizumab or Cetuximab, in Patients with Advanced Solid Tumors

R. Perets,S.M. Stemmer,R. Geva, T. Golan, M. Fakih, J.E. Cohen,C. Lieu, Z. Jin, P. Lorusso, I. Friedman, M. Hakim, D. Haves Ziv,S. Hashmueli, I. Mandel, T. Ben Moshe, N. Crawford,G. Abbadessa, R. Perez, M. Wu,M. Borad

Annals of Oncology (2024)

引用0浏览0引用

Safety and Clinical Activity of JNJ-78306358, a Human Leukocyte Antigen-G (HLA-G) X CD3 Bispecific Antibody, for the Treatment of Advanced Stage Solid Tumors

Ravit Geva,Maria Vieito, Jorge Ramon,Ruth Perets,Manuel Pedregal,Elena Corral,Bernard Doger,Emiliano Calvo, Jorge Bardina,Elena Garralda,Regina J. Brown,James G. Greger, Shujian Wu, Douglas Steinbach, Tsun-Wen Sheena Yao, Yu Cao,Josh Lauring, Ruchi Chaudhary, Jaymala Patel, Bharvin Patel,Victor Moreno

CANCER IMMUNOLOGY IMMUNOTHERAPYno. 10 (2024)

引用0浏览0WOS引用

The Effect of Long-Standing Lymphopenia after Radiation Therapy on Survival in Rectal Cancer

Viacheslav Soyfer, Eli Lugovoy,Alla Nikolaevski-Berlin,Yasmin Korzets,Albert Schlocker,Orit Gutfeld,Inna Ospovat,Uri Amit,Tatiana Rabin, Yasmin Filomena Natan-Oz,Leor Zach,Ofer Merimsky,Ravit Geva, Sharon Peles,Ido Wolf

SURGICAL ONCOLOGY-OXFORD (2024)

引用0浏览0WOS引用

Early Activity and Biomarker Evaluation of NT219 in Combination with Cetuximab in a Phase 1/2 Study of Recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)

Ari J. Rosenberg, Shumei Kato,Daniel Johnson,Aron Popovtzer, Vi K. Chiu,Ravit Geva, Hava Ben-David, Tomer Meirson, Michael Schickler, Hadas Reuveni

CANCER RESEARCHno. 6 (2024)

引用0浏览0引用

Treatments and Clinical Outcomes in Stage II Colon Cancer Patients with 12-Gene Oncotype DX Colon Recurrence Score® Assay-Guided Therapy: Real-World Data

B. Brenner, K. Shulman,A. Hubert,S. Man,R. Geva,I. Ben-Aharon, S. Fennig,M. Mishaeli,N. Yarom,G. Bar-Sela,R. Brenner,A. Shai,F. L. Baehner, C. Russell,L. Soussan-Gutman,H. Voet,A. Bareket-Samish,N. Liebermann

ESMO OPENno. 8 (2024)

引用0浏览0WOS引用

27O Interim Results of a Phase I/II Trial of NT219 in Combination with Cetuximab in Patients with Advanced/metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Ari Rosenberg, Shumei Kato,Daniel Johnson,Aron Popovtzer,Vi K. Chiu,Ravit Geva,Michael Schickler, Hadas Reuveni

ESMO open (2024): 102355-102355

引用0浏览0引用

Abstract 5181: Early Activity and Biomarker Evaluation of NT219 in Combination with Cetuximab in a Phase 1/2 Study of Recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)

Ari J. Rosenberg, Shumei Kato,Daniel Johnson,Aron Popovtzer,Vi K. Chiu,Ravit Geva, Hava Ben‐David,Tomer Meirson,Michael Schickler, Hadas Reuveni

Cancer researchno. 6_Supplement (2024): 5181-5181

引用0浏览0引用

Abstract 6552: Intratumoral (ITu) delivery of mRNA-2752 encoding human OX40L/IL-23/IL-36γ in combination with durvalumab induces an immunostimulatory effect within the tumor microenvironment (TME) of patients with advanced solid tumors

Michael Abadier,Ryan J. Sullivan,Jacky Chow,Vasudha Sehgal,Randy F. Sweis,Adil Daud,Ronnie Shapira-Frommer,Ruth Perets,Shivaani Kummar,Meredith McKean,Ravit Geva,Manish R. Patel,Adnan Khattak, Pablo Fernandez-Peñas,Sima Zacharek, Natalia Wahl, Russell M. Walker, Linh Van,Praveen Aanur, Jim Ward,Khanh T. Do,Georgina V. Long

Cancer Researchno. 6_Supplement (2024): 6552-6552

引用0浏览0引用

Abstract CT104: Results from a Phase 1 Study of the Anti-Immunoglobulin-like Transcript 4 (ILT4) Monoclonal Antibody MK-4830 Plus Pembrolizumab in Patients with Previously Treated Advanced Solid Tumors

Lillian L. Siu,Marta Gil-Martin,Byoung Chul Cho,Ruth Perets,John Hilton,Ravit Geva,Iwona Lugowska,Martin Gutierrez,Marcelo Bonomi,Rafal Dziadziuszko,Drew Rasco,Eytan Ben-Ami,Cristina P. Rodriguez,Shabana Siddiqi,Nicole Myer,Leah Suttner, Douglas Wilson, Ombololaji O. Akala,Maria de Miguel

Cancer Researchno. 7_Supplement (2024)

引用0浏览0引用

Results from a Phase 1 Study of the Anti-Immunoglobulin-like Transcript 4 (ILT4) Monoclonal Antibody MK-4830 Plus Pembrolizumab in Patients with Previously Treated Advanced Solid Tumors

Lillian L. Siu, Marta Gil-Martin, Byoung Chul Cho, Ruth Perets,John Hilton,Ravit Geva,Iwona Lugowska,Martin Gutierrez, Marcelo Bonomi,Rafal Dziadziuszko,Drew Rasco, Eytan Ben-Ami,Cristina P. Rodriguez,Shabana Siddiqi, Nicole Myer,Leah Suttner, Douglas Wilson, Ombololaji O. Akala, Maria de Miguel

CANCER RESEARCHno. 7 (2024)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn